Mereo BioPharma Group plc - Sponsored ADR

MREO Healthcare Biotechnology

Mereo BioPharma Group plc - Sponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $500,000.00, down 95.0% from fiscal 2023. In the quarter to June 2026, EPS grew 52.3% and free cash flow grew 21.0%, each against the same quarter a year earlier.

0.30 0.01 −3.23%
Market cap
$49.3M
P/E
0.0×
Fwd P/E
−8.3×
Dividend yield
—
F-score
n/a
Altman Z
−9.11
Beneish M
n/a
Dividend safety
n/a
Older periods Sep '25 Dec '25 Mar '26 Jun '26
ROE

+8 more TTM periods

(69.79%) (82.21%) (75.87%) (67.85%)
ROA
(58.41%) (68.48%) (65.56%) (57.73%)
ROIC
0.00% 0.00% 0.00% 0.00%
Return on Tangible Assets
(89.28%) (102.50%) (105.19%) (101.16%)
Average Days of Receivables
— — — —
Free Cash Flow per Share
(0.21) (0.20) (0.17) (0.16)
Free Cash Flow
(33.03) (31.29) (27.25) (25.65)
Other line items

Show all line items

Columns are period end dates